|Articles|March 24, 2023

Webinar from the Food and Drug Administration: Cannabis and Cannabis-Derived Products

Author(s)Erin McEvoy

The Food and Drug Administration (FDA) will hold an educational webinar on cannabis and cannabis-derived products for healthcare practitioners in late March.

The Food and Drug Administration (FDA) will hold an interactive and educational webinar on cannabis as part of its Division of Drug Information in the Center for Drug Evaluation and Research (CDER) series of webinars (1). The webinars are intended for health care professionals and students, physicians, physician assistants, nurses, pharmacists, and pharmacy technicians with the goal of learning about the FDA and drug regulation (1).

The webinar, which will be presented on Tuesday, March 28, 2023 at 10:00am PDT, is called “FDA Drug Topics: Cannabis and Cannabis-Derived Products–For Healthcare Practitioners” and is presented by CDER’s Office of Communication, Division of Drug Information (DDI).

“This webinar will provide a general understanding of the Cannabis sativa L. plant and how products are generally produced utilizing cannabis raw materials,” states the description (1). “The presentation will explain why manufacturing controls surrounding cannabis and cannabis-derived products are an integral part of protecting the public health. Will provide attendees with greater knowledge of the many products available on the marketplace, a discussion on potential benefits and risks, ways to report adverse events associated with these products to FDA, as well as suggestions on how to create a safe space to discuss patient use of these products.”

“The recording of the webinar will be available on our Division of Drug Information Webinars webpage later this week and will also be available as a Home Study course providing CE credit in a few weeks,” the announcement also stated (1,2).

Register here for the webinar.

References

  1. https://www.fda.gov/about-fda/fda-pharmacy-student-experiential-program/fda-drug-topics-cannabis-and-cannabis-derived-products-healthcare-practitioners-march-28-2023
  2. https://ceportal.fda.gov/index.cfm?do=cus.runEventReport&reportName=EventAnnouncementForm&style=2&preview=1&eventId=7354

Related to this article

2025 Medical Cannabis Roundup
Let’s take a look at the 2025 cannabis coverage on medical cannabis research and medicine to catch up on industry trends and innovations.
Image | adobe.stock/Stock Rocket
Let’s take a look at the 2025 cannabis coverage on cannabis research to catch up on industry trends and innovations.
Manipulating Cannabis Genetics: Pulling Levers to Increase  Phytochemical Composition
Cannabis genetics fundamentally dictate the plant's potential for chemical signatures, including cannabinoid and terpene profiles, and physical traits, such as yield. Cultivators use selective techniques, such as "stacking," to enhance specific compounds. Ultimately, successful cultivation involves balancing superior genetics with environmental "levers" to optimize gene expression and create targeted strains.
Image | adobe.stock/Maksim Kabakou
It’s that time of year again—the Cannabis Science and Technology (CST) top 10 articles from the previous year. CST published a wide variety of content throughout 2025. Here is just a small snippet of some of the top articles that our readers enjoyed. See if any of your favorites made the list!